In June 2020, Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize Genmab’s next-generation bispecific antibody products epcoritamab, DuoHexaBody®-CD37 and DuoBody®-CD3x5T4. The companies also entered into a discovery research collaboration to select and develop up to four additional differentiated next-generation antibody-based product candidates. For epcoritamab Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales. For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates developed as a result of the companies’ discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan.

In June 2013, Genmab entered an agreement to develop a new antibody-drug conjugate (ADC) camidanlumab tesirine, combining Genmab’s HuMax^®-TAC antibody with ADC Therapeutics’ PBD-based warhead and linker technology. In March 2015, Genmab decided not to exercise its co-development right for camidanlumab tesirine and now has a 25% ownership stake in the product.

Genmab has a direct license for exclusive worldwide rights to Amgen’s patent estate relating to antibodies to IL15 and the IL15 receptor. In July 2003, Amgen exercised its commercialization options for the HuMax^®-IL15 antibody program (now AMG 714). Amgen has partnered with Provention Bio to conduct and fund a Phase 2b trial with AMG 714 in non-responsive celiac disease (NRCD).

In May 2012, Genmab licensed HuMax^®-IL8 to Cormorant Pharmaceuticals. Following the acquisition of Cormorant by Bristol Myers Squibb (BMS), the HuMax^®-IL8 agreement was transferred to BMS.

In August 2012, Genmab announced a global license and development agreement for daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Genmab granted Janssen an exclusive worldwide license to develop and commercialize daratumumab.

Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab in 2006. The full rights to ofatumumab were subsequently transferred from GSK to Novartis in 2015. Novartis is now responsible for the development and commercialization of ofatumumab in all potential indications. Genmab is entitled to potential regulatory and sales milestones, in addition to 10 percent royalty payment of net sales. Novartis is fully responsible for all costs associated with developing and commercializing ofatumumab.

In May 2001, Genmab entered a collaboration with Roche to develop human antibodies to disease targets identified by Roche. In 2002, this alliance was expanded, and Roche made an equity investment in Genmab. Under the agreement, Genmab will receive milestones as well as royalty payments on successful products and, in certain circumstances, Genmab could obtain rights to develop products based on disease targets identified by Roche.

In September 2010, Genmab and Seattle Genetics entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seattle Genetics’ ADC technology with its HuMax^®-TF antibody and Seattle Genetics has the right to exercise a co-development option for any resulting ADC products at the end of Phase 1 clinical development. In September 2014, Genmab entered into an additional ADC collaboration with Seattle Genetics to utilize Seattle Genetics’ ADC technology with Genmab’s HuMax^®-AXL antibody.

In October 2011, Genmab and Seattle Genetics entered into a commercial license and collaboration agreement for antibody-drug conjugates (ADCs). Under the agreement, Genmab was granted rights to utilize Seattle Genetics ADC technology with its HuMax^®-TF antibody. In 2017, Seattle Genetics exercised its option to co-develop tisotumab vedotin, and the companies share all future costs and profits for the product on a 50:50 basis.